Literature DB >> 16616802

Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments.

J M van der Vaart1, N Pant, D Wolvers, S Bezemer, P W Hermans, K Bellamy, S A Sarker, C P E van der Logt, L Svensson, C T Verrips, L Hammarstrom, B J W van Klinken.   

Abstract

Apart from the use of oral rehydration solution, there are currently no treatment modalities for rotavirus induced diarrhoea, which is particularly relevant to developing countries. Fragments derived from llama heavy chain antibodies were previously shown to be highly stable, efficiently produced in yeast and exhibiting high epitope specific affinity. We now aim to demonstrate that these antibody fragments are capable of reducing morbidity of rotavirus induced diarrhoea. Here we show the isolation of rotavirus specific antibody fragments and their capability of reducing the morbidity of rotavirus induced diarrhoea in vivo in mice. They could provide a treatment modality for the moderation of human rotavirus infections having a significant impact on the course of an often fatal childhood disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616802     DOI: 10.1016/j.vaccine.2006.02.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

Review 1.  Phage display--a powerful technique for immunotherapy: 2. Vaccine delivery.

Authors:  Justyna Bazan; Ireneusz Całkosiński; Andrzej Gamian
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

2.  Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.

Authors:  Christophe Blanchetot; Dennis Verzijl; Azra Mujić-Delić; Leontien Bosch; Louise Rem; Rob Leurs; C Theo Verrips; Michael Saunders; Hans de Haard; Martine J Smit
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

3.  Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.

Authors:  Greg Hussack; Mehdi Arbabi-Ghahroudi; Henk van Faassen; J Glenn Songer; Kenneth K-S Ng; Roger MacKenzie; Jamshid Tanha
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

4.  An Exopolysaccharide-Deficient Mutant of Lactobacillus rhamnosus GG Efficiently Displays a Protective Llama Antibody Fragment against Rotavirus on Its Surface.

Authors:  Beatriz Álvarez; Kasper Krogh-Andersen; Christian Tellgren-Roth; Noelia Martínez; Gökçe Günaydın; Yin Lin; M Cruz Martín; Miguel A Álvarez; Lennart Hammarström; Harold Marcotte
Journal:  Appl Environ Microbiol       Date:  2015-06-19       Impact factor: 4.792

5.  Evaluation of antidiphtheria toxin nanobodies.

Authors:  Ghada H Shaker
Journal:  Nanotechnol Sci Appl       Date:  2010-06-17

6.  Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.

Authors:  Daisuke Tokuhara; Beatriz Álvarez; Mio Mejima; Tomoko Hiroiwa; Yuko Takahashi; Shiho Kurokawa; Masaharu Kuroda; Masaaki Oyama; Hiroko Kozuka-Hata; Tomonori Nochi; Hiroshi Sagara; Farah Aladin; Harold Marcotte; Leon G J Frenken; Miren Iturriza-Gómara; Hiroshi Kiyono; Lennart Hammarström; Yoshikazu Yuki
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

7.  Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice.

Authors:  Lorena Garaicoechea; Aurelien Olichon; Gisela Marcoppido; Andrés Wigdorovitz; Marina Mozgovoj; Linda Saif; Thomas Surrey; Viviana Parreño
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

8.  Recombinant monovalent llama-derived antibody fragments (VHH) to rotavirus VP6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea.

Authors:  Celina G Vega; Marina Bok; Anastasia N Vlasova; Kuldeep S Chattha; Silvia Gómez-Sebastián; Carmen Nuñez; Carmen Alvarado; Rodrigo Lasa; José M Escribano; Lorena L Garaicoechea; Fernando Fernandez; Karin Bok; Andrés Wigdorovitz; Linda J Saif; Viviana Parreño
Journal:  PLoS Pathog       Date:  2013-05-02       Impact factor: 6.823

Review 9.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

Review 10.  Therapeutic Applications of Functional Nanomaterials for Prostatitis.

Authors:  Chun-Ping Liu; Zi-De Chen; Zi-Yan Ye; Dong-Yue He; Yue Dang; Zhe-Wei Li; Lei Wang; Miao Ren; Zhi-Jin Fan; Hong-Xing Liu
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.